Nutriband CEO Gareth Sheridan Named EY Entrepreneur of the Year 2025 Finalist
TL;DR
Nutriband CEO Gareth Sheridan named finalist in 2025 EY Entrepreneur of the Year Awards, showcasing leadership in life sciences sector.
Sheridan transformed Nutriband into a U.S.-listed company focused on transdermal drug delivery and abuse-deterrent technologies with lead product AVERSA.
AVERSA technology by Nutriband addresses critical pain management gaps, aiming to prevent misuse and abuse of opioid patches for a better future.
27 Irish entrepreneurs, including CEO Gareth Sheridan, to compete for overall Entrepreneur of the Year title at gala event in November, showcasing innovation.
Found this article helpful?
Share it with your network and spread the knowledge!
Gareth Sheridan, CEO of Nutriband Inc., has been selected as a finalist in the Established category of the 2025 EY Entrepreneur of the Year Awards, marking a significant recognition of his leadership in the life sciences sector. The prestigious award acknowledges Sheridan's transformative role in developing Nutriband from an early-stage startup to a publicly listed company focused on innovative pharmaceutical technologies.
As one of 27 Irish entrepreneurs recognized this year, Sheridan represents a select group of business leaders from 24 companies generating over €1 billion in annual revenue. The EY Entrepreneur of the Year program highlights executives who demonstrate exceptional innovation, strategic vision, and meaningful impact in their respective industries.
Nutriband's primary focus is developing transdermal pharmaceutical products, with its lead product AVERSA™ representing a critical advancement in pain management safety. The abuse-deterrent technology aims to prevent misuse, diversion, and accidental exposure of drugs with high abuse potential, addressing a significant challenge in the pharmaceutical landscape.
The recognition comes with notable opportunities for Sheridan, including participation in a CEO retreat in Japan and potential selection for the overall Entrepreneur of the Year title. The final award will be presented at a gala event in November, providing a platform to showcase Nutriband's innovative approach to pharmaceutical technology.
Sheridan's nomination underscores the importance of developing safer pharmaceutical delivery systems, particularly in the context of ongoing challenges with opioid medications. By focusing on abuse-deterrent technologies, Nutriband demonstrates a commitment to patient safety and responsible medical innovation.
The EY Entrepreneur of the Year Award serves not just as a personal achievement for Sheridan, but also as a validation of Nutriband's strategic direction and potential to make meaningful contributions to healthcare technology. This recognition may further position the company as a leader in developing advanced pharmaceutical delivery solutions that prioritize patient safety and reduce potential drug misuse.
Curated from InvestorBrandNetwork (IBN)
